Both perforin and FasL are required for optimal CD8 T cell control of autoreactive B cells and autoantibody production in parent-into-F1 lupus mice.

Both perforin and FasL are required for optimal CD8 T cell control of autoreactive B cells and autoantibody production in parent-into-F1 lupus mice.
复制标题

DOI:
10.1016/j.clim.2018.06.007
复制
发表时间:
2018-09
期刊:
Clinical immunology (Orlando, Fla.)
影响因子:
--
通讯作者:
Via CS
Via CS
中科院分区:
其他
文献类型:
--
作者:
Soloviova K;Puliaiev M;Puliaev R;Puliaeva I;Via CS

文献摘要

参考文献

被引文献

相似文献

为了测试穿孔素(pfp)与FasL在CTL控制自身反应性B细胞扩增中的相对作用,我们使用了小鼠移植物抗宿主病的亲本进入F1模型,其中供体CD8 CTL通过消除活化的自身反应性B细胞来预防狼疮样疾病。接受pfp或FasL缺陷供体T细胞的F1小鼠表现出中间短期表型。纯化的正常CD4 T细胞与pfp或FasL缺陷型CD8 T细胞亚群配对导致受损的宿主B细胞消除和轻度狼疮样疾病,这在两个实验组中大致相当。因此,除了在肿瘤和细胞内病原体控制中的主要作用外,pfp介导的CD8 CTL杀伤在控制自身反应性B细胞扩增和狼疮下调中起重要作用,其与FasL杀伤介导的作用相当。重要的是,这两种途径都是激活的自身反应性B细胞的最佳消除所必需的。
To test the relative roles of perforin (pfp) vs. FasL in CTL control of autoreactive B cell expansion, we used the parent-into-F1 model of murine graft-vs.–host disease in which donor CD8 CTL prevent lupus like disease by eliminating activated autoreactive B cells. F1 mice receiving either pfp or FasL defective donor T cells exhibited an intermediate short-term phenotype. Pairing of purified normal CD4 T cells with either pfp or FasL defective CD8 T cell subsets resulted in impaired host B cell elimination and mild lupus like disease that was roughly equivalent in the two experimental groups. Thus, in addition to major roles in tumor and intracellular pathogen control, pfp mediated CD8 CTL killing plays a significant role in controlling autoreactive B cell expansion and lupus downregulation that is comparable to that mediated by FasL killing. Importantly, both pathways are required for optimal elimination of activated autoreactive B cells.
DOI: 10.1056/nejmoa021933
发表时间: 2003-10-16
影响因子: 158.5
作者:
Arbuckle, MR;McClain, MT;Harley, JB
通讯作者: Harley, JB
DOI: 10.1172/jci117051
发表时间: 1994-03-01
影响因子: 15.9
作者:
MYSLER, E;BINI, P;ELKON, KB
通讯作者: ELKON, KB
DOI: 10.1016/j.clim.2010.01.005
发表时间: 2010-07
期刊: Clinical immunology (Orlando, Fla.)
影响因子: --
作者:
Foster AD;Haas M;Puliaeva I;Soloviova K;Puliaev R;Via CS
通讯作者: Via CS
DOI: 10.1172/jci118855
发表时间: 1996-08-01
影响因子: 15.9
作者:
Koshy, M;Berger, D;Crow, MK
通讯作者: Crow, MK
DOI: 10.1002/eji.1830250923
发表时间: 1995-09-01
影响因子: 5.4
作者:
KOH, DR;HO, A;MAK, TW
通讯作者: MAK, TW